SilverArc Capital and Devesh Gandhi report 2.83% Avalo Therapeutics (AVTX) holding

Rhea-AI Filing Summary

SilverArc Capital Management, LLC and Devesh Gandhi have filed a Schedule 13G reporting a passive ownership stake in Avalo Therapeutics, Inc. Class A common stock. As of the event date, they beneficially own 524,436 shares, representing 2.83% of the outstanding Class A common stock.

All 524,436 shares are reported with shared voting and shared dispositive power, and neither SilverArc nor Gandhi has sole voting or dispositive power over any shares. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Avalo Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

05338F306

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

SilverArc Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 524,436.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 524,436.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

524,436.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.83 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

Devesh Gandhi

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 524,436.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 524,436.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

524,436.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.83 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Dr Suite 321 Wayne, PA, 19087
Item 2.
(a)	Name of person filing: SilverArc Capital Management, LLC ("SilverArc") and Devesh Gandhi ("Gandhi" and together with SilverArc, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: 20 Park Plaza, Suite 620 Boston, MA 02116
(c)	Citizenship: SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 524436
(b)	Percent of class: 2.83 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 524436
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 524436
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SilverArc Capital Management, LLC

Signature:	Devesh S. Gandhi
Name/Title:	Sole Member of SilverArc Capital Management, LLC
Date:	02/04/2026

Devesh Gandhi

Signature:	Devesh S. Gandhi
Name/Title:	Sole Member of SilverArc Capital Management, LLC
Date:	02/04/2026

FAQ

What stake in Avalo Therapeutics (AVTX) does SilverArc Capital report on this Schedule 13G?

SilverArc Capital Management, LLC and Devesh Gandhi report beneficial ownership of 524,436 shares of Avalo Therapeutics Class A common stock, representing 2.83% of the class. This ownership level is below the 5% threshold that typically signals larger, more concentrated positions.

Who are the reporting persons on the Avalo Therapeutics (AVTX) Schedule 13G?

The reporting persons are SilverArc Capital Management, LLC, a Delaware limited liability company, and Devesh Gandhi, a U.S. citizen. Gandhi signs as Sole Member of SilverArc Capital Management, LLC, indicating his control of the filing entity in relation to these Avalo Therapeutics shares.

How much voting power do SilverArc and Devesh Gandhi have over Avalo Therapeutics (AVTX) shares?

SilverArc and Devesh Gandhi report 0 shares with sole voting power and 524,436 shares with shared voting power. They likewise report 0 shares with sole dispositive power and 524,436 shares with shared dispositive power, meaning all reported influence over these shares is shared, not individual.

Is the Avalo Therapeutics (AVTX) position held for control purposes according to this Schedule 13G?

No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Avalo Therapeutics. It also notes they are not held in connection with any control-related transaction.

What does Item 5 ‘Ownership of 5 Percent or Less’ indicate for Avalo Therapeutics (AVTX)?

Item 5 confirms that the reporting persons’ stake represents 5 percent or less of Avalo Therapeutics’ Class A common stock. Specifically, they disclose beneficial ownership of 2.83%, clarifying that their position is relatively small in relation to the total outstanding shares.

What key dates are associated with this Avalo Therapeutics (AVTX) Schedule 13G filing?

The Date of Event Which Requires Filing is listed as 12/31/2025, reflecting when the ownership position triggered the reporting requirement. The certification is signed and dated by Devesh S. Gandhi on 02/04/2026, confirming the accuracy of the disclosed ownership details.